![Jonathan Kearsey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan Kearsey
Gründer bei Leads To Development
Aktive Positionen von Jonathan Kearsey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
APIM Therapeutics AS
![]() APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Corporate Officer/Principal | - | - |
Leads To Development | Direktor/Vorstandsmitglied | - | - |
Gründer | - | - |
Karriereverlauf von Jonathan Kearsey
Ehemalige bekannte Positionen von Jonathan Kearsey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Diatos SA
![]() Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Technik-/Wissenschafts-/F&E-Leiter | - | 15.09.2009 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Jonathan Kearsey
University of London | Doctorate Degree |
Statistik
International
Frankreich | 3 |
Vereinigtes Königreich | 3 |
Norwegen | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Diatos SA
![]() Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Health Technology |
APIM Therapeutics AS
![]() APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Health Technology |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Leads To Development |
- Börse
- Insiders
- Jonathan Kearsey
- Erfahrung